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Repolarization Gradients in Brugada Syndrome. Introduction: Brugada syndrome (BrS) is
associated with loss of Na+ channel function and increased risks of a ventricular tachycardia exacerbated
by ﬂecainide but reduced by quinidine. Previous studies in nongenetic models have implicated both altered
conduction times and repolarization gradients in this arrhythmogenicity. We compared activation latencies
and spatial differences in action potential recovery between different ventricular regions in a murine
Scn5a+/− BrS model, and investigated the effect of ﬂecainide and quinidine upon these.
Methods and Results: Langendorff-perfused wild-type and Scn5a+/− hearts were subjected to regular
pacing and a combination of programmed electrical stimulation techniques. Monophasic action potentials
were recorded from the right (RV) and left ventricular (LV) epicardium and endocardium before and
followingﬂecainide(10μM)orquinidine(5μM)treatment,andactivationlatenciesmeasured.Transmural
repolarization gradients were then calculated from the difference between neighboring endocardial and
epicardial action potential durations (APDs). Scn5a+/− hearts showed decreased RV epicardial APDs,
accentuating RV, but not LV, transmural gradients. This correlated with increased arrhythmic tendencies
compared with wild-type. Flecainide increased RV transmural gradients, while quinidine decreased them,
in line with their respective pro- and antiarrhythmic effects. In contrast, Scna5+/− hearts showed slowed
conduction times in both RV and LV, exacerbated not only by ﬂecainide but also by quinidine, in contrast
to their differing effects on arrhythmogenesis.
Conclusion: We use a murine genetic model of BrS to systematically analyze LV and RV action potential
kinetics for the ﬁrst time. This establishes a key role for accentuated transmural gradients, speciﬁcally in
the RV, in its arrhythmogenicity. (J Cardiovasc Electrophysiol, Vol. 21, pp. 1153-1159, October 2010)
arrhythmia, ion channels, sudden death, action potentials, conduction velocity, Brugada syndrome, sodium
channels, ventricular tachycardia, antiarrhythmic drugs, repolarization
Introduction
Brugada syndrome (BrS) is associated with a loss of Na+
channel function and increased risks of polymorphic ven-
tricular tachycardia (VT), potentially leading to sudden car-
diac death. The arrhythmogenicity in BrS is thought to be
a result of electrophysiological alterations localized to the
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right ventricle, reﬂected in ST elevation in the right precor-
dial leads, right bundle branch block and changes speciﬁc to
right ventricle (RV) epicardial action potential (AP) wave-
forms.1 Previous studies have implicated either slowed RV
AP conduction2,3 or alterations in AP repolarization1,4 in the
arrhythmogenesisassociatedwithBrS.Thus,ononehand,re-
ducedNa+ currentsinBrSwouldbeexpectedtocompromise
AP conduction. On the other, their reduction in relationship
to Ito currents in BrS would shorten the RV epicardial APD
and consequently permit reentrant waves.5
Experimental models for BrS have involved a number
of pharmacological manipulations in canine systems. These
have involved use of agents producing K+ channel opening
by pinacidil, Na+ channel block by ﬂecainide, Ca2+ channel
block by verapamil, increased [Ca2+]o, metabolic inhibition
or simulated ischemia. Such studies have implicated repolar-
ization gradients caused by regional heterogeneities in elec-
trical activity. However, there is uncertainty as to whether
such pharmacological systems provide accurate or complete
replicationofthephysiologicalchangesunderlyingBrS.Fur-
thermore, the pharmacological manipulations themselves in-
herently lack a speciﬁcity of action. Experimental systems
using genetic modiﬁcations to replicate BrS may provide a
more speciﬁc model to clarify physiological abnormalities
associated with the disease condition.
Thus far, only the Scn5a gene, which encodes the car-
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connection with BrS. Our previous studies using a het-
erozygotic Scn5a+/− mouse have recapitulated features of
the human clinical condition in demonstrating an enhanced
arrhythmogenesis that is exacerbated by ﬂecainide and re-
lieved by quinidine. This model has previously shown a 50%
reduction in the transmembrane Na+ current and evidence
for slowed ventricular and atrioventricular conduction.6 As
yet, no evidence has been found for accentuated repolariza-
tion gradients in this model although to date no study of the
RV has been made.7
In the present experiments, we seek for the ﬁrst time in a
genetic whole-heart BrS model to discriminate the contribu-
tionsofalterationsinconductionandrepolarizationgradients
in the arrhythmogenesis, and to localize the pathophysiolog-
ical mechanism in the RV. We were particularly interested in
the effects upon conduction velocity and repolarization gra-
dients of 2 clinically used drugs: ﬂecainide, which is known
tounmaskventriculararrhythmogenesisinotherwiseasymp-
tomatic BrS patients,8 and quinidine, which has shown pro-
tective actions in symptomatic BrS.9 We correlate alterations
in RV gradients in the BrS model that are speciﬁcally ex-
acerbated by ﬂecainide, with the observed arrhythmogenic
properties and with clinical ﬁndings implicating the RV in
the arrhythmogenic mechanism. This may contribute to fu-
ture work investigating possible pharmacological treatments
for a disease for which the current mainstay of treatment is
implantable cardioverter deﬁbrillator (ICD) implantation.5
Methods
Langendorff Perfusion
Mice aged 4–8 months were obtained from breeding
pairs of heterozygote Scn5a+/− and wild-type (WT) in-
bred 129/sv mice initially supplied by Harlan (UK). Ex-
periments used a Langendorff-perfused preparation adapted
for the murine heart, as described previously.10 Following
the start of perfusion, viable hearts suitable for subsequent
experimentation regained a pink coloration and spontaneous
rhythmic contraction with warming. Where used, 10 μM
ﬂecainide and 5 μM quinidine (Sigma-Aldrich, Poole, UK)
dissolved in buffer solution were perfused for 15 minutes
priortoandthroughoutdataacquisition.Concentrationswere
within the same range as known clinical therapeutic levels
(ﬂecainide: 0.2–0.9 mg L−1; quinidine: 2.0–5.0 mg L−1).11
All procedures conformed to the UK Animals (Scientiﬁc
Procedures) Act 1986.
Monophasic Action Potential Recording
Monophasic action potentials (MAPs) were recorded us-
ing an established contact-electrode technique detailed pre-
viously.12 Epicardial MAPs were recorded from the basal
surface of the ventricular epicardium, both on the left and on
the right using a miniaturized MAP electrode tip (Linton In-
struments,HarvardApparatus,UK).EndocardialMAPsused
electrodes constructed from galvanically chlorided, Teﬂon-
coated 0.25 mm diameter silver wire introduced into the
ventricular cavity through a small access window created in
the ventricular wall. Pilot experiments showed that both sets
of electrodes provided equivalent MAP traces. MAP signals
were ampliﬁed and band-pass ﬁltered between 0.1 Hz and
300 Hz (Neurolog AC ampliﬁers and ﬁlters Models NL104
and NL125/6, respectively: Digitimer, Welwyn Garden City,
Herts, UK), then digitized using a 1401plus interface (Cam-
bridge Electronic Design, Cambridge, UK). Paired platinum
stimulating electrodes paced the heart high on the interven-
tricular septum.
The stimulating electrode and the epicardial LV and RV
recording electrodes were clamped at a constant position
through all experiments. This was at a distance of approxi-
mately 10 mm between stimulating and each recording elec-
trode, although it was slightly larger for the LV than for
the RV. This distance allowed the hearts to be placed into
the rig, with the stimulating electrode coming into contact
with the septum and the recording electrodes coming into
contact with the left and right ventricles. While the direct
absolute distance between electrodes would not necessarily
reﬂect the path through which the electrical signal would be
conducted in the spherical whole heart, the fact that the dis-
tance was maintained between experiments allowed consis-
tent measurements of activation latencies. As the clamp was
secure throughout experiments, this distance was constant to
∼0.5 mm, i.e., 5% of the distance between stimulating and
recording electrodes.
For measurement of APDs, hearts were paced at 8 Hz for
5minutesandrecordingsweremadeatLVandRV,epicardial
andendocardialsites.Foractivationlatencies,onlyepicardial
sites were used, as the point of endocardial recording could
not be accurately determined. For calculations of arrhythmia
incidence, as well as regular 8 Hz pacing, the hearts also
underwent an S1S2 protocol, imposing S2 extrastimuli fol-
lowing pacing S1 stimulus trains at S1–S2 intervals, reduced
by 1 ms between successive drive trains until the preparation
became refractory, and a dynamic pacing protocol progres-
sively increasing pacing frequency every 100 beats. Thus for
each heart, 12 recordings in total were made, with 3 proto-
cols and 4 cardiac regions employed. MAP recordings were
made both before and during treatment with either ﬂecainide
(10 μM) or quinidine (5 μM).
Data Analysis
MAP waveforms were analyzed using Spike2 software
(Cambridge Electronic Design). The point of maximum pos-
itive deﬂection was considered the point of 0% repolariza-
tion; that of full return to baseline of 100% repolarization.
The intervening waveform was described in terms of APDx
measurements at x = 90% (APD90), 70% (APD70) and 50%
(APD50) repolarization. The effect of heterogeneous repo-
larization on the difference between different cardiac regions
was expressed empirically as the difference ( APDx) be-
tween neighboring APD values: LV transmural = LV en-
docardial APD—LV epicardial APD, RV transmural = RV
endocardial APD—RV epicardial APD, epicardial transven-
tricular = LV epicardial APD—RV epicardial APD, endo-
cardial transventricular = LV endocardial APD—RV endo-
cardial APD.
Activation latencies for MAPs recorded from the RV and
LV epicardium were measured from the stimulus time to
peak amplitude of the MAP to give an indication of con-
duction velocities. With the positions of the stimulating and
recording electrodes constant between experiments, compar-
isons could be made between WT and Scn5a+/− hearts, and
before and after drug. However, as the distance from stimu-
lating electrode on the septum was slightly greater to the LV
recordingelectrodethantheRVrecordingelectrode,nodirectMartin et al. Repolarization Gradients in Brugada Syndrome 1155
Figure 1. Representative RV epicardial MAP records from Scn5a+/−
hearts during regular 8 Hz pacing. The vertical markers below each trace
indicate stimulus timings. The y-axis is the MAP voltage normalized to peak
MAP deﬂection. Hearts were either resistant to arrhythmia (A) or showed
VEs (B), nsVT (lasting less than 1 second) (C), or VT (lasting more than 1
second) (D).
comparisoncouldbemadebetweenLVandRV.Forthecalcu-
lationofarrhythmicincidence,eachrunwaslabeledaseither
nonarrhythmicorshowingoneof3possiblearrhythmias:VT
(exceeding 1 second in duration), nonsustained VT (nsVT,
lasting less than 1 second), or having one or more ventricular
ectopic (VE).
Statistical Procedures
Sixteen WT and 16 Scn5a+/− mice were used in our
experiments, as this was a number sufﬁcient to enable cat-
egorical statistical analysis for incidence of arrhythmogene-
sis. Although we also attempted quantitative measurements
in all 16, we only included measurements from hearts whose
MAPs strictly attained the accepted criteria of rapid upstroke
phases, consistent amplitudes, smooth contoured repolariza-
tionphasesandstablebaselines13 inall4cardiacregions.We
consequently used 12 hearts of each genotype for the calcu-
lation of activation latencies and repolarization gradients. In
all cases, half of each group was exposed to ﬂecainide and 6
to quinidine.
All results were expressed as mean ± S.E.M. values. The
signiﬁcance of differences in arrhythmic incidences used
TABLE 1
The Incidence of Arrhythmogenesis in WT and Scn5a+/− Hearts Characterized as Showing One of Three Possible Arrhythmias: VT (Exceeding 1 second
in Duration), nsVT (Lasting Less Than 1 second), and One or More VEs
WT Scn5a+/−
No Drug Flecainide 10 μM Quinidine 5 μM No Drug Flecainide 10 μM Quinidine 5 μM
VT 3/192 6/96 3/96 21/192 16/96 1/96
nsVT 5/192 2/96 4/96 8/192 12/96 1/96
VEs 2/192 0/96 1/96 3/192 9/96 1/96
Total 10/192 (5.2) 8/96 (8.3) 8/96 (8.3) 32/192 (16.7)∗ 37/96 (38.5)∗† 3/96 (3.1)∗†
Hearts showing more than one of these arrhythmias were marked as showing the more potentially clinically signiﬁcant arrhythmic event, VEs being the least
and VT being the most signiﬁcant. Recordings were made from hearts either in the absence or presence of either ﬂecainide (10 μM) or quinidine (5 μM).
Results are expressed both as numbers of test runs showing arrhythmia out of the total, and as percentages in parentheses. Sixteen WT and 16 Scn5a+/−
hearts were used before drug, and 8 of each were exposed to each drug treatment. Each heart was tested in 4 cardiac regions and with 3 different protocols,
leading to 192 runs before drug for each genotype, and 96 each for each drug. The results of Chi-squared tests are shown, sorted by genotype (corrected P <
0.05 signiﬁcance denoted by∗) and drug condition (denoted by†).
Fisher exact and Chi-squared tests. Differences in activation
latencies, APDs and  APDs between different regions were
analyzed using Student’s t-tests; these were paired where re-
sults could be compared from the same heart. Previously,
ANOVA with post-hoc Tukey’s honestly signiﬁcant different
tests have been used to analyze multiple paired data sets;
however, this assumes that all data sets are compared with
each other and thus increases the likelihood of Type II er-
rors. We accordingly adopted a procedure using a modiﬁed
Bonferronicorrectionfactor14 usingthefollowingprocedure:
t-tests were grouped into independent data sets and the sig-
niﬁcance values rank-ordered from smallest to largest. The
signiﬁcanceofthetestwithP-valueatalpha/(numberoftests)
was evaluated and, if statistically signiﬁcant, the test result
from the test with the next smallest signiﬁcance value was
selected and evaluated at alpha/(number of tests—1), and so
on. Alpha was set at 0.05.
Results
Arrhythmias Were Unmasked by Flecainide in Scn5a+/−
Mice, but Reduced by Quinidine
WT and Scn5a+/− hearts could either be resistant to
arrhythmia or could show VEs, nsVT, or polymorphic VT
duringrecording.Figure1illustratesthesepossibleoutcomes
by showing RV epicardial MAP records from Scn5a+/−
hearts during regular 8 Hz pacing. Similar traces could be
obtained from WT, and from other cardiac regions in both
Scn5a+/− and WT.
WT hearts showed low incidences of arrhythmia, even
when subjected to PES protocols or with ﬂecainide or
quinidine treatment. In contrast, Scn5a+/− hearts showed
markedlygreaterarrhythmictendencies.Inbothcases,Fisher
exact tests excluded signiﬁcant differences in arrhythmia in-
cidence between cardiac region or stimulus protocol (regular
pacing, S1S2 or dynamic pacing protocols: see Methods).
These results were therefore combined for Chi-squared test-
ing sorted by genotype and drug condition (Table 1). WT
hearts showed only small, insigniﬁcant increases in their low
incidence of arrhythmogenesis with either drug treatment.
However,ﬂecainideandquinidineexertedcontrastingeffects
in the Scn5a+/− hearts through all cardiac regions studied
andprotocolsemployed.Scn5a+/−heartsshowedmarkedly
increasedarrhythmogenicitywithﬂecainide,whilequinidine
reduced arrhythmic incidence in Scn5a+/− hearts to levels1156 Journal of Cardiovascular Electrophysiology Vol. 21, No. 10, October 2010
Figure 2. (A) MAP trace from a typical Scn5a+/− heart, showing measurement of activation latency from stimulus to peak amplitude of the MAP. (B)
Activation latencies in the RV and LV epicardium from WT and Scn5a+/− hearts, before and after the addition of ﬂecainide or quinidine. Open symbols
denote LV; ﬁlled symbols denote RV. Twelve WT and 12 Scn5a+/− hearts were used, with 6 of each exposed to each drug. t-tests comparing values before
and after drug have signiﬁcant values (with P < 0.05) denoted by ∗. t-tests comparing WT and Scn5a+/− have signiﬁcant values denoted by †. The same
signiﬁcant results occurred both in RV and LV, therefore only one set of symbols is shown.
statistically indistinguishable from those normally observed
in WT.
Scn5a+/− Hearts Show Slowed Conduction, Which is
Exacerbated by Both Flecainide and Quinidine
In comparison with WT hearts, Scn5a+/− hearts showed
longer activation latencies, corresponding to slowed conduc-
tion(Fig. 2). However, thiseffect was not localized tothe RV
epicardium, and was also true to the same extent in the LV.
Both ﬂecainide and quinidine increased activation latencies
to similar extents (t-test: P = 0.09) in both the LV and RV of
both WT and Scn5a+/− hearts.
Scn5a+/− and WT Hearts Show Regional Differences in
AP Waveforms
We then undertook a systematic comparison of epicar-
dial and endocardial MAP waveforms in both RV and LV.
Figure 3A–D shows typical MAP waveforms in a typical
Scn5a+/− heart, overlaid to demonstrate the contrasts in LV
and RV transmural (Fig. 3A,B) and epicardial and endocar-
dial transventricular gradients (Fig. 3C,D). Figure 3E shows
typicalRVepicardialandendocardialMAPsfromaWTheart
forcomparison,whileFigure3FoverlaysWTandScn5a+/−
RV epicardial MAPs. Figure 4A shows the 4 areas of a typi-
cal Scn5a+/− heart, with APD70 values for each area shown
in normal type. Arrows between the regions show the direc-
tion of each gradient, with its magnitude in italic type. Fig-
ure4BshowsAPD70sforWTandScn5a+/−heartsrecorded
from the 4 examined ventricular regions and (C) the result-
ing gradients between them expressed as  APD70s across
neighboring regions. Thus,
• Both untreated WT and Scn5a+/− hearts showed signif-
icant repolarization gradients varying between different
cardiac regions. These gradients were particularly strong
atearlier(i.e.,70%repolarization)phasesoftheAPrecov-
ery and arose from the following ﬁndings of the individual
MAP durations. Endocardial MAP durations were very
similar in the LV and RV. In contrast, epicardial MAP du-
rations in the RV were shorter than those in the LV of
both WT and Scn5a+/− hearts. Finally, both the RV and
LV endocardial MAPs were longer than their correspond-
ing epicardial MAPs, giving statistically signiﬁcant differ-
ences in the RV in both WT and Scn5a+/− hearts. These
differences resulted in RV transmural gradients that were
signiﬁcantly greater than the corresponding LV gradients,
particularly in the Scn5a+/− hearts.
• Scn5a+/− hearts showed generally shorter APDs than
WT. Although this was true of all ventricular regions, this
only reached statistical signiﬁcance in the RV epicardium.
This resulted in signiﬁcantly greater RV transmural gradi-
ents, as reﬂected in the  APD50,  APD70, and  APD90
values in Scn5a+/− hearts compared with WT.
Effects of Flecainide and Quinidine on AP Waveforms in
Murine Scn5a+/− and WT Hearts
The ﬁndings above implicate the RV in the arrhythmo-
genicity shown by Scn5a+/− through accentuated RV trans-
mural repolarization gradients, brought about by shortened
RV epicardial APDs. This hypothesis could be tested by
assessing the extent to which the actions of ﬂecainide and
quinidine upon these gradients in Scn5a+/− compared with
WT paralleled their respective pro- and antiarrhythmic ac-
tions in Scn5a+/−.
The resulting experiments split the WT and Scn5a+/−
heartsintoageandsexmatchedgroupsforstudiesbeforeand
followingtreatmentwith10μMﬂecainideor5μMquinidine
(n = 6 hearts in each group). Figure 5 shows MAP wave-
forms from RVs of the same WT and Scn5a+/− hearts as in
Figure 3, now following introduction of (A, B) ﬂecainide
or (C, D) quinidine, overlaying epicardial and endocardial
MAPs to illustrate how both drugs affect the RV transmu-
ral repolarization gradients. Then shown are (E) APD70s
from the RV epicardium, and (F) the resultant RV trans-
mural  APD70s for WT and Scn5a+/− hearts before and
after drug treatment.
These demonstrated the following:
• In WT hearts, ﬂecainide shortened the APD values in all 4
ventricular regions investigated, but doing so signiﬁcantly
only for RV epicardium. This resulted in increases in the
RV transmural gradients, but which only reached signiﬁ-
cance for the APD90.
• In WT hearts, quinidine increased the APD values in all
the ventricular regions studied, but did so most noticeablyMartin et al. Repolarization Gradients in Brugada Syndrome 1157
Figure3. TypicalMAPwaveformsunder8Hzpacingin(A)–(D)Scn5a+/−
hearts, with traces overlaid to demonstrate the different resultant gradients:
(A) LV epicardial and LV endocardial, (B) RV epicardial and RV endo-
cardial, (C) LV and RV epicardial, (D) LV and RV endocardial. (E) RV
epicardial and endocardial MAP waveforms in a typical WT heart and (F)
RV epicardial MAPs compared between typical WT and Scn5a+/− hearts.
The vertical arrow in each trace marks the pacing stimulus, which appears
as an artifact on the trace.
in the RV epicardium, reaching signiﬁcance here for all 3
repolarizations. The RV transmural gradient was reduced,
but again only reaching signiﬁcance for the APD90.
• In Scn5a+/− hearts, ﬂecainide shortened the APD values
in all the ventricular regions studied. Again, this effect
was most noticeable in the RV epicardium. This resulted
inmarkedincreasesintheRVtransmuralgradientwhether
measured as  APD50,  APD70,o r APD90. There were
no signiﬁcant alterations in either the transventricular or
the LV transmural gradient.
• In contrast, quinidine lengthened the APDs in all ventric-
ular regions in Scn5a+/− hearts, again reaching signiﬁ-
cance speciﬁcally in the RV epicardium. These changes
markedly decreased the RV transmural gradients to levels
similar to that seen in WT before pharmacological treat-
ment, but did not signiﬁcantly reduce either the transven-
tricular or LV transmural gradients.
The pharmacological maneuvers thus exerted similar pat-
terns of effects upon Scn5a+/− as WT hearts, particularly
involving the RV epicardium, with quinidine reducing, and
ﬂecainide increasing, the RV transmural gradients. However,
the latter maneuvers acted upon a situation of already accen-
Figure 4. (A) Four chambers of a typical Scn5a+/− heart are displayed
diagrammatically: left epicardium, right epicaridum, left endocardium, and
right endocardium, with their respective APD70 values in normal font. Ar-
rows between the 4 areas depict the gradients between them, with  APD70
values in italic font. Data are expressed in ms as mean +/− SEM. Thus the
gradients are calculated: LV transmural = LV endocardial APD—LV epi-
cardial APD; RV transmural = RV endocardial APD—RV epicardial APD;
epicardial transventricular = LV epicardial APD—RV epicardial APD; en-
docardial transventricular = LV endocardial APD—RV endocardial APD.
(B) APD70 values obtained from the 4 ventricular regions and (C) gradients
for WT and for Scn5a+/− hearts at the APD70 level. Twelve WT and 12
Scn5a+/− hearts were used. t-tests comparing APD70 values between car-
diac regions within both WT and Scn5a+/− hearts have signiﬁcant values
(with P < 0.05) denoted by †. t-tests for both APD70 and  APD70 values
comparing WT and Scn5a+/− have signiﬁcant values denoted by ∗.
tuated right transmural gradients in the Scn5a+/−, thereby
giving very strongly positive RV transmural gradients.
Discussion
The BrS has been associated with a heterogeneous group
of genotypes; nevertheless, ∼15% of BrS patients do show
a loss-of-function Na+ channel mutation. This prompted the
recent development and use of a Scn5a+/− murine genetic
model in studies of the BrS condition. Having ﬁrst con-
ﬁrmed arrhythmogenicity in the Scn5a+/− hearts, we sys-
tematically investigated arrhythmic incidence in all 4 car-
diac regions with 3 different stimulation protocols for the
ﬁrst time. We demonstrated that this model reproduces the
clinical BrS condition by displaying ventricular arrhythmias
that were exacerbated by ﬂecainide, in line with its clinical
effects in unmasking ventricular arrhythmogenesis in other-
wise asymptomatic BrS patients,8 and reduced by quinidine,
in line with its protective action on symptomatic BrS.9 Equal
arrhythmia incidence in all 4 cardiac regions is consistent
with arrhythmic activity arising in any one cardiac region1158 Journal of Cardiovascular Electrophysiology Vol. 21, No. 10, October 2010
Figure 5. (A)–(D) MAP waveforms from RVs of (A), (C) WT and (B), (D)
Scn5a+/− hearts subject to 8 Hz pacing following introduction of (A),
(B) ﬂecainide and (C), (D) quinidine. (E) APD70 measurements in the RV
epicardium and (F) RV transmural gradients for WT and Scn5a+/− hearts
before and following addition of either ﬂecainide or quinidine. Six hearts
were used in each group. t-tests comparing values before and after drug
have signiﬁcant values denoted by ∗.
ultimately spreading throughout both ventricles, therefore
involving the entire heart. That stimulation protocol did not
signiﬁcantly affect arrhythmogenic incidence is consistent
with clinical observations that the inducibility of VT during
PES fails to predict sudden cardiac death in BrS patients.15
The differences in arrhythmic properties could be asso-
ciated with both delayed epicardial activation latencies and
increased right transventricular repolarization gradients in
Scn5a+/− hearts. Such ﬁndings complement previous re-
portsofScn5a+/−myocytes havingNa+ currentamplitudes
reduced to ∼50% of the levels shown by WT, as well as
slowed AP conduction.6 Our study supports earlier work
measuring regional APDs in canine16 and rat17 WT sys-
tems, as well as molecular and cellular studies of regional
ion channel location.18-21 The present results also extend
ﬁndings of altered repolarization gradients in canine wedge
preparations that mimic BrS by pharmacological rather than
genetic means.22 However, our study is the ﬁrst using a ge-
netic model for BrS and in which all 4 cardiac regions have
been systematically compared.
Comparison of such altered conduction and repolariza-
tion properties through the epicardia and endocardia of the
right and left ventricles demonstrated that while both slowed
conduction and accentuated repolarization gradients could
potentially contribute to the arrhythmogenic mechanism in
BrS, it was only the repolarization abnormalities that could
be localized to the RV epicardium. Thus, while conduction
slowing may provide a background arrhythmic substrate, the
RV origin of the arrhythmias in clinical BrS suggests that
the heightened repolarization gradients in this region may
be the speciﬁc trigger. These ﬁndings also shed light on the
pathophysiology of ST elevation seen in BrS, for which 2
mechanisms have been proposed: either it is due to the dif-
ference in AP morphology between the RV epicardium and
endocardium,23 or it is secondary to conduction slowing.24
The localization of the enhanced repolarization gradients to
the RV may suggest that the physiological mechanism un-
derlying ST elevation is also more closely related to a repo-
larization disorder than a delay in depolarization.
The increase in both latencies and transmural gradients
produced by ﬂecainide correlates with its proarrhythmic ef-
fects in both the model and clinical situations. The former
ﬁndingparallelstheclinicalﬁndingsimplicatingslowedcon-
duction in the RV outﬂow tract in Brugada patients2 that is
exacerbated with class 1C drug challenge.3 The latter result
supports ﬁndings in canine models, where high ﬂecainide
concentrations result in loss of the AP dome and marked
AP abbreviation,25 and clinical studies demonstrating that
pilsicainide administration in BrS patients triggers T wave
alternans, which is known to reﬂect enhanced spatial and
temporal dispersion of repolarization.26 However, whereas
the action of ﬂecainide on activation latencies occurred in
both the RV and the LV, its action on transmural repolar-
ization gradients was again signiﬁcant speciﬁcally for the
RV.
The increase in conduction delay produced by quinidine
was not unexpected given its effect in blocking Na+ chan-
nels, but is in contrast to its effect in decreasing arrhythmic
incidence in murine Scn5a+/− and human BrS hearts. On
the other hand, its action in reducing transmural repolar-
ization gradients correlated with its antiarrhythmic effects.
Quinidine has correspondingly been shown to reverse the
associated electrocardiographic abnormalities and prevent
phase 2 reentry and polymorphic VT in experimental ca-
nine BrS models,22 and normalize the ST segment in clinical
circumstances.27,28
The main limitations of the study are associated with the
differencesbetweenmouseandhumanphysiology.Thesmall
size of the mouse heart means that strong electrotonic forces
may act to minimize the effect of any spatial heterogeneities
that are created and reduce their potential to create reentrant
substrate. The AP morphology differs between humans and
mice, as mice use less L-type Ca channel current, which
means that the mouse AP does not have a plateau phase
and has a shorter APD.29 This means that the spike and
dome morphology present in larger mammals is not present
in our mouse model. However, despite these difﬁculties, we
were able to demonstrate a clear propensity to arrhythmia inMartin et al. Repolarization Gradients in Brugada Syndrome 1159
our BrS mouse model and correlate this with enhanced RV
transmural gradients.
Conclusion
In summary, this study has for the ﬁrst time in a geneti-
cally modiﬁed BrS model assessed activation latency, APDs
and derived AP repolarization gradients from 4 regions of
the heart under a range of stimulation protocols and a range
of pharmacological conditions. The experiments correlate
the increased arrhythmogenicity in Scn5a+/− hearts with
both increased activation latency and decreased RV epicar-
dial APD and increased RV  APDs. However, while con-
duction delay was not localized speciﬁcally to the RV and
wasincreasedbybothﬂecainideandquinidine,therespective
pro- and antiarrhythmic effects of ﬂecainide and quinidine
could be directly correlated with their actions in increasing
and decreasing RV  APDs. Thus, these ﬁndings, while not
excluding a contribution of conduction delay, support most
closely an arrhythmogenic trigger based on reentry from ab-
normal repolarization gradients between RV epicardial and
endocardial sites.
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